Cargando…
Therapeutic vaccines and cancer: focus on DPX-0907
In an attempt to significantly enhance immunogenicity of peptide cancer vaccines, we developed a novel non-emulsion depot-forming vaccine platform called DepoVax™ (DPX). Human leukocyte antigen (HLA)-A2 restricted peptides naturally presented by cancer cells were used as antigens to create a therape...
Autores principales: | Karkada, Mohan, Berinstein, Neil L, Mansour, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930480/ https://www.ncbi.nlm.nih.gov/pubmed/24596453 http://dx.doi.org/10.2147/BTT.S55196 |
Ejemplares similares
-
Plasma biomarker analysis of ovarian cancer patients undergoing immunotherapy with therapeutic cancer vaccine DPX-Survivac
por: Karkada, Mohan, et al.
Publicado: (2015) -
Immunological and polyfunctional T cell profiling following therapy with DPX-Survivac as a predictive tool of vaccine efficacy
por: Karkada, Mohan, et al.
Publicado: (2013) -
Multi-modal treatment with peptide vaccine, metronomic cyclophosphamide and anti-PD1 monoclonal antibody provides effective control of tumors in multiple models
por: Weir, Genevieve, et al.
Publicado: (2014) -
Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response
por: Weir, Genevieve M, et al.
Publicado: (2014) -
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients
por: Berinstein, Neil L, et al.
Publicado: (2012)